Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabis sativa oil, often referred to as CBD oil when derived from low-THC varieties, has been increasingly studied for its potential anxiolytic (anxiety-reducing) effects. Scientific interest centers primarily on cannabidiol (CBD), a non-intoxicating component of Cannabis sativa. Preclinical studies (animal models) and a limited number of human clinical trials suggest that CBD may reduce anxiety, potentially through interaction with serotonin receptors and other neurochemical pathways. For example, several small placebo-controlled trials have shown that CBD can reduce anxiety in social anxiety disorder and in anxiety induced by public speaking.

However, the overall quality and quantity of evidence is still limited. Many studies are small, short-term, and use varying doses and formulations. Reviews by organizations such as the National Academies of Sciences and the World Health Organization note that while preclinical evidence is promising, robust clinical evidence is still lacking. Additionally, products labeled as "cannabis sativa oil" may vary widely in their CBD and THC content, further complicating interpretation of results and recommendations.

In summary, while there is some scientific evidence to support the use of CBD-rich Cannabis sativa oil for anxiety, it remains preliminary. Larger, well-designed clinical trials are needed to determine efficacy, safety, optimal dosing, and long-term effects. As of now, the evidence rating for its use in anxiety disorders is 2 out of 5, reflecting suggestive but not definitive data.

More about cannabis sativa oil
More about Anxiety Disorders

Other ingredients used for Anxiety Disorders

Other health conditions supported by cannabis sativa oil

Products containing cannabis sativa oil